OAM
COGT icon

Oppenheimer Asset Management’s Cogent Biosciences COGT Stock Holding History

Oppenheimer Asset Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214K Sell
5,528
-82
-1% -$2.87K ﹤0.01% 1068
2026
Q1 		$216K Buy
+5,610
New +$207K ﹤0.01% 1047

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Oppenheimer Asset Management's COGT Position: Q2 2026 in Review

Oppenheimer Asset Management reduced its Cogent Biosciences (COGT) stake by 1.5% in Q2 2026, selling an estimated $2.87K and leaving 5,528 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #1068.

Oppenheimer Asset Management first reported a position in COGT in Q1 2026 and has held it in 2 quarters since. The position peaked at $216K in Q1 2026. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Oppenheimer Asset Management held 5,528 shares of Cogent Biosciences worth $214K as of Q2 2026.
  • Oppenheimer Asset Management sold 82 Cogent Biosciences shares in Q2 2026, an estimated $2.87K.
  • Cogent Biosciences made up ﹤0.01% of Oppenheimer Asset Management's portfolio in Q2 2026, its #1068 holding.
  • Oppenheimer Asset Management first reported a position in Cogent Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Oppenheimer Asset Management's Cogent Biosciences position peaked at $216K in Q1 2026.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.